Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 11/20 | 0.72 |
| ▸ | PTAFR | P25105 | 3/20 | 0.71 |
| ▸ | FNTA | P49354 | 5/20 | 0.70 |
| ▸ | FNTB | P49356 | 5/20 | 0.70 |
| ▸ | SLC6A15 | Q9H2J7 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4460572 | 0.88 | HRH1 (0.82) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL31384618 | 0.88 | HRH1 (0.82) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL29626502 | 0.88 | HRH1 (0.82) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL24045915 | 0.86 | HRH1 (0.69) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL8958672 | 0.85 | PTAFR (0.75) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL20777155 | 0.85 | PTAFR (0.75) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL11925299 | 0.84 | HRH1 (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL10123931 | 0.84 | HRH1 (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL8889578 | 0.84 | SLC6A15 (0.79) | HRH1PTAFRFNTAFNTBSLC6A15 | |
| SCHEMBL8876967 | 0.83 | PTAFR (1.00) | HRH1PTAFRFNTAFNTBSLC6A15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101782-B2 | Drug hybrid of rivastigmine or physostigmine with tranylcypromine, amoxapine, desipramine, nortriptyline, protriptyline, fluoxetine, fluvoxamine, paroxetine, duloxetine, betahistine, amlodipine, proylhexedrine, rimantadine, desloratadine; Alzheimer's disease; Parkinson's disease, impairment in memory | COLUCID PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20080261950-A1 | Compounds that inhibit cholinesterase | COLUCID PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261950-A1 | Compounds that inhibit cholinesterase | ACHE, BCHE, CHAT | HRH1 765/4885PTAFR 2122/4885FNTA 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.